Stockopedia Review 2026: StockRanks, Screens, and the Verdict

Stockopedia is worth it in 2026 if you pick individual stocks and want a fast way to screen thousands of companies by quality, value, and momentum instead of building spreadsheets by hand. It is not worth it if you already trust your own screening workflow, or you trade options and futures rather than long-term equity positions.

I started testing Stockopedia in March 2026 against my usual routine of Finviz exports and a homemade scoring sheet. The pitch is simple: instead of manually weighting valuation multiples against momentum indicators, Stockopedia does it for you and hands you a single StockRank number for each of the 35,000-plus stocks in its database. The company has run this model since 2013 and publishes its own track record rather than hiding behind vague performance claims, which is unusual in a market full of stock-picking tools that promise an edge but never show their homework. This review covers what StockRanks actually measure, how the screener holds up against Finviz Elite and TradingView, what 2026 pricing looks like, and who should, and should not, pay for it.

Is Stockopedia worth the price in 2026?

Yes, for a specific kind of user. Stockopedia earns its $600-a-year US and India plan if you manage a portfolio of 15 or more individual stocks and currently spend hours each week screening or ranking candidates by hand. If you hold only a handful of positions, or already pay for Morningstar Investor or Seeking Alpha Premium for similar data, the overlap makes a second subscription hard to justify.

The value case rests almost entirely on time saved, not on some claimed alpha edge. Building a multi-factor screen from scratch, pulling quality metrics like return on capital, value ratios like EV to EBIT, and momentum measures like 6-month relative strength, easily takes 3 to 5 hours to set up and needs monthly upkeep after that. Stockopedia's StockRanks do that calculation overnight for every stock in its coverage universe and refresh it daily. In my testing, rebuilding a comparable 5-factor screen across 30 stocks took about 40 minutes in Stockopedia versus most of an afternoon pulling data from three separate sources by hand.

For an investor who screens more than once a week, the time saved alone tends to cover the subscription cost within the first month.

What is the StockRanks system and how does it work?

StockRanks assign every covered stock three sub-scores, Quality, Value, and Momentum, each from 0 to 100, then blend them into a single composite StockRank. A stock scoring 95 or above on all three is labeled a Super Stock inside the platform, while one scoring low across the board gets flagged as a Sucker Stock, a term Stockopedia uses to warn users away from statistically dangerous combinations, like a cheap valuation paired with deteriorating fundamentals and falling price momentum.

Stockopedia's own backtested data puts the win rate of stocks ranked 90 or above at approximately 62% over rolling 12-month periods since 2013, a track record the company publishes directly rather than a marketing estimate.

Does Stockopedia's performance data hold up under scrutiny?

Beyond the individual StockRank win-rate figures, Stockopedia tracks a series of public model portfolios built entirely from its own screens. The best known, NAPS, has returned 358% over 10.75 years since launch, an annualized rate of about 15.2%, according to Stockopedia's own published performance data. That figure is not audited by a third party the way a mutual fund's returns would be, so treat it the way you would any vendor-reported track record: directionally useful, not a guarantee.

A 15.2% annualized return over 10.75 years is a real, published number, but it reflects a model portfolio under ideal execution, not a guarantee of what any individual subscriber will earn following the same screens.

How do you set up your first screen in Stockopedia?

Most new users can build and save a working multi-factor screen in under 15 minutes using a Guru Screen template as the starting point instead of a blank filter list.

How does Stockopedia's screener compare to Finviz and TradingView?

Finviz Elite and TradingView both offer screening, but neither combines a proprietary composite ranking with 350-plus fundamental filters the way Stockopedia does. Finviz Elite, at roughly $39.50 a month, is faster for pure technical and price-based screens and has a cleaner charting interface for that purpose. TradingView's screener is strongest for combining chart-based alerts with basic fundamental filters across its large user base, but it does not offer anything like the multi-factor StockRank composite.

Stockopedia is the only one of the three that reduces quality, value, and momentum into a single ranked number you can sort an entire watchlist by; the other two leave that synthesis step to the user.

What does Stockopedia cost and which plan fits you?

As of 2026, Stockopedia sells three main tiers. A single-region plan, India-only coverage for example, runs $395 a year. The US and India plan, which covers 13,500-plus US and Indian stocks with full StockReports and StockRanks, runs $600 a year, or roughly $75 a month if billed monthly instead of annually. A Customise plan adds more regions, up to the full 35,000-plus stock universe across 61 exchanges, priced on request with a discount for bundling two or more regions.

For a US-focused investor, the realistic entry price is $600 a year, not the cheaper India-only tier that shows up on some marketing pages.

Who should use Stockopedia, and who should skip it?

• You hold 15 or more individual stocks and rebalance or screen at least monthly
• You currently build valuation or momentum screens by hand in a spreadsheet
• You invest across more than one country or exchange, not just the US
• You want a repeatable, rules-based process instead of a gut-feel watchlist
• You don't already pay for an overlapping tool like Morningstar Investor for the same data

Stockopedia fits an investor who runs a concentrated portfolio of 15 to 40 individual stocks and wants a repeatable ranking process; it is a poor fit for someone who mostly dollar-cost-averages into index funds or trades primarily options and futures.

The verdict on Stockopedia in 2026

Stockopedia is not trying to be everything. It does not chart, it does not execute trades, and it will not tell you the exact minute to sell. What it does is compress the quality, value, and momentum research most active stock-pickers already do by hand into a single ranked number, refreshed daily across a much larger universe than a spreadsheet could realistically cover.

At $600 a year for US and India coverage, Stockopedia earns its keep for anyone screening more than a handful of stocks a month, and the 14-day trial plus 30-day refund window make it a low-risk way to test whether the StockRanks system fits your process before committing.